切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2022, Vol. 11 ›› Issue (03) : 172 -175. doi: 10.3877/cma.j.issn.2095-3216.2022.03.011

综述

血液透析患者透析低血压的研究进展
杨洁1, 王红叶1, 张蕊1,()   
  1. 1. 150001 哈尔滨,哈尔滨医科大学附属第二医院肾内科
  • 收稿日期:2022-03-09 出版日期:2022-06-28
  • 通信作者: 张蕊

Research progress of intradialysis hypotension in hemodialysis patients

Jie Yang1, Hongye Wang1, Rui Zhang1,()   

  1. 1. Department of Nephrology, Second Hospital Affiliated to Harbin Medical University, Harbin 150001, Heilongjiang Province, China
  • Received:2022-03-09 Published:2022-06-28
  • Corresponding author: Rui Zhang
引用本文:

杨洁, 王红叶, 张蕊. 血液透析患者透析低血压的研究进展[J]. 中华肾病研究电子杂志, 2022, 11(03): 172-175.

Jie Yang, Hongye Wang, Rui Zhang. Research progress of intradialysis hypotension in hemodialysis patients[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(03): 172-175.

透析低血压(IDH)是维持性血液透析(MHD)的常见并发症之一,且发生率始终居高不下,影响患者的生活质量及长期预后。因此规避IDH风险十分必要。近年来,随着病理生理研究的不断深入,IDH优化防治方面的进展迅速,如生物反馈技术、低温透析、中医疗法等。本文围绕IDH定义、危害、病理生理、防治策略等最新进展进行综述,旨在为防治IDH提供资料和参考。

Intradialysis hypotension (IDH) is one of the common complications of maintenance hemodialysis (MHD), and its incidence remains high, affecting the quality of life and long-term prognosis of patients. Therefore, it is necessary to avoid IDH risks. In recent years, with the deepening of pathophysiological research, rapid progress has been made in the optimization of prevention and treatment of IDH, such as biofeedback technology, cold dialysis, and traditional Chinese medicine therapy. This article reviewed the latest progress in the definition, harm, pathophysiology, and prevention and treatment strategies of IDH, aiming to provide information and reference for the prevention and treatment of IDH.

图1 透析中低血压预防措施注:EBPG:欧洲最佳实践指南;IDH:透析低血压
[1]
Kuipers J, Verboom LM, Ipema KJR, et al. The prevalence of intradialytic hypotension in patients on conventional hemodialysis: a systematic review with meta-analysis [J]. Am J Nephrol, 2019, 49(6): 497-506.
[2]
Kooman J, Basci A, Pizzarelli F, et al. EBPG guideline on haemodynamic instability [J]. Nephrol Dial Transplant, 2007, 22(Suppl 2): ii22-ii44.
[3]
K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J]. Am J Kidney Dis, 2005, 45(4 Suppl 3): S1-S153.
[4]
Kim KY, Park HS, Kim JS, et al. Comparison of intradialytic blood pressure metrics as predictors of all-cause mortality [J]. Clin Kidney J, 2021, 14(12): 2600-2605.
[5]
Yu J, Liu Z, Shen B, et al. Intradialytic hypotension as an independent risk factor for long-term mortality in maintaining hemodialysis patients: a 5-year follow-up cohort study [J]. Blood Purif, 2018, 45(4): 320-326.
[6]
Chang TI, Paik J, Greene T, et al. Intradialytic hypotension and vascular access thrombosis [J]. J Am Soc Nephrol, 2011, 22(8): 1526-1533.
[7]
Mc Causland FR, Tumlin JA, Roy-Chaudhury P, et al. Intradialytic hypotension and cardiac arrhythmias in patients undergoing maintenance hemodialysis: results from the monitoring in dialysis study [J]. Clin J Am Soc Nephrol, 2020, 15(6): 805-812.
[8]
Cedeño S, Desco M, Aleman Y, et al. Intradialytic hypotension and relationship with cognitive function and brain morphometry [J]. Clin Kidney J, 2020, 14(4): 1156-1164.
[9]
Jansen MA, Hart AA, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients [J]. Kidney Int, 2002, 62(3): 1046-1053.
[10]
Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes [J]. Clin J Am Soc Nephrol, 2009, 4(5): 914-920.
[11]
Yu J, Chen X, Li Y, et al. High ultrafiltration rate induced intradialytic hypotension is a predictor for cardiac remodeling: a 5-year cohort study [J]. Ren Fail, 2021, 43(1): 40-48.
[12]
Macedo E, Karl B, Lee E, et al. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients [J]. Crit Care, 2021, 25(1): 18.
[13]
Mc Causland FR, Claggett B, Sabbisetti VS, et al. Hypertonic mannitol for the prevention of intradialytic hypotension: a randomized controlled trial [J]. Am J Kidney Dis, 2019, 74(4): 483-490.
[14]
Aronoff GR. The effect of treatment time, dialysis frequency, and ultrafiltration rate on intradialytic hypotension [J]. Semin Dial, 2017, 30(6): 489-491.
[15]
Ettema EM, Zittema D, Kuipers J, et al. Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and meta-analysis [J]. Am J Nephrol, 2014, 39(2): 100-109.
[16]
Marshall MR, Vandal AC, de Zoysa JR, et al. Effect of low-sodium versus conventional sodium dialysate on left ventricular mass in home and self-care satellite facility hemodialysis patients: a randomized clinical trial [J]. J Am Soc Nephrol, 2020, 31(5): 1078-1091.
[17]
Gabutti L, Bianchi G, Soldini D, et al. Haemodynamic consequences of changing bicarbonate and calcium concentrations in haemodialysis fluids [J]. Nephrol Dial Transplant, 2009, 24(3): 973-981.
[18]
Mustafa RA, Bdair F, Akl EA, et al. Effect of lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta-analysis [J]. Clin J Am Soc Nephrol, 2016, 11(3): 442-457.
[19]
Yoowannakul S, Kotecha T, Fontana M, et al. Do pre-hemodialysis estimates of extracellular volume excess using bioimpedance and N-terminal brain natriuretic peptide correlate with cardiac chamber size measured by magnetic resonance imaging? [J]. Ther Apher Dial, 2019, 23(4): 362-368.
[20]
Jelicic I. Relationship of a food intake during hemodialysis and symptomatic intradialytic hypotension [J]. Hemodial Int, 2021, Epub ahead of print.
[21]
Kim TW, Chang TI, Kim TH, et al. Association of ultrafiltration rate with mortality in incident hemodialysis patients [J]. Nephron, 2018, 139(1): 13-22.
[22]
Leung KCW, Quinn RR, Ravani P, et al. Randomized crossover trial of blood volume monitoring-guided ultrafiltration biofeedback to reduce intradialytic hypotensive episodes with hemodialysis [J]. Clin J Am Soc Nephrol, 2017, 12(11): 1831-1840.
[23]
Dasgupta I, Thomas GN, Clarke J, et al. Associations between hemodialysis facility practices to manage fluid volume and intradialytic hypotension and patient outcomes [J]. Clin J Am Soc Nephrol, 2019, 14(3): 385-393.
[24]
Brunelli SM, Sibbel S, Do TP, et al. Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: a retrospective observational study [J]. Am J Kidney Dis, 2015, 66(4): 655-665.
[25]
Bullen A, Rifkin D, Trzebinska D. Individualized cool dialysate as an effective therapy for intradialytic hypotension and hemodialysis patients′ perception [J]. Ther Apher Dial, 2019, 23(2): 145-152.
[26]
Maheshwari V, Lau T, Samavedham L, et al. Effect of cool vs warm dialysate on toxin removal: rationale and study design [J]. BMC Nephrol, 2015, 16: 25.
[27]
Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD [J]. J Am Soc Nephrol, 2010, 21(10): 1798-1807.
[28]
林玲,彭梅,罗凯,等. 参麦注射液对血液透析相关性低血压患者血压、血清白蛋白及透析充分性的影响[J]. 河北中医2019, 41(5): 706-709.
[29]
于晓瑜,陆丹. 针灸并用预防血液透析相关性低血压的疗效观察[J]. 中国中西医结合肾病杂志2018, 19(4): 347-348.
[30]
Rhee SY, Song JK, Hong SC, et al. Intradialytic exercise improves physical function and reduces intradialytic hypotension and depression in hemodialysis patients [J]. Korean J Intern Med, 2019, 34(3): 588-598.
[31]
Frankenfield DL, Weinhandl ED, Powers CA, et al. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D [J]. Am J Kidney Dis, 2012, 59(5): 670-681.
[32]
Roberts MA, Pilmore HL, Ierino FL, et al. The β-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: a randomized controlled trial [J]. Am J Kidney Dis, 2016, 67(6): 902-911.
[33]
Assimon MM, Brookhart MA, Fine JP, et al. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis [J]. Am J Kidney Dis, 2018, 72(3): 337-348.
[34]
Brunelli SM, Cohen DE, Marlowe G, et al. The impact of midodrine on outcomes in patients with intradialytic hypotension [J]. Am J Nephrol, 2018, 48(5): 381-388.
[35]
Razeghi E, Dashti-Khavidaki S, Nassiri S, et al. A randomized crossover clinical trial of sertraline for intradialytic hypotension [J]. Iran J Kidney Dis, 2015, 9(4): 323-330.
[36]
Imai E, Fujii M, Kohno Y, et al. Adenosine A1 receptor antagonist improves intradialytic hypotension [J]. Kidney Int, 2006, 69(5): 877-883.
[1] 张亚龙, 邱涛, 刘一霆, 王天宇, 孔晨阳, 喻博, 周江桥. 术前透析方式及时长对肾移植预后的影响[J]. 中华移植杂志(电子版), 2023, 17(02): 98-103.
[2] 杨静, 顾红叶, 赵莹莹, 孙梦霞, 查园园, 王琪. 老年血液透析患者短期死亡的影响因素及列线图预测模型的预测作用[J]. 中华肾病研究电子杂志, 2023, 12(05): 254-259.
[3] 任加发, 邬步云, 邢昌赢, 毛慧娟. 2022年急性肾损伤领域基础与临床研究进展[J]. 中华肾病研究电子杂志, 2023, 12(05): 276-281.
[4] 王珊, 马清, 姚兰, 杨华昱. 老年维持性血透患者叶酸治疗与miR-150-5p血清水平的相关性研究[J]. 中华肾病研究电子杂志, 2023, 12(03): 139-144.
[5] 苏朝江, 许厅, 黄海龙, 刘俪婷, 熊智倩, 姜燕, 陈彦, 刘宗旸. 5G远程机器人超声在血透患者血管通路评估中的应用[J]. 中华肾病研究电子杂志, 2023, 12(02): 105-108.
[6] 邵俊侨, 王明. 维持性血液透析患者睡眠障碍的中医药治疗[J]. 中华肾病研究电子杂志, 2023, 12(02): 97-100.
[7] 李峻, 林莉, 王俭梅, 李芬, 刘莉莉, 汪星玉, 丁洁. 黄芪当归贴膏对维持性血液透析患者自体动静脉内瘘的保护作用[J]. 中华肾病研究电子杂志, 2023, 12(02): 87-92.
[8] 徐艺琳, 刘军, 张文颖, 魏敏, 李海伦. 个体化预测维持性血液透析发生动静脉内瘘栓塞风险的列线图模型建立[J]. 中华肾病研究电子杂志, 2023, 12(02): 81-86.
[9] 葛杰, Mali Niroj, 陈广梅, 樊文星, 何佳敏, 曹玲艳. 中性粒细胞/淋巴细胞比值与维持性血液透析患者透析充分性的相关性分析[J]. 中华肾病研究电子杂志, 2022, 11(06): 327-331.
[10] 金刚, 李英真, 施维, 李博. 帕金森病在病理生理学中的研究进展[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 315-319.
[11] 周加军, 余永武, 周涵, 张凌. 358例继发性甲状旁腺功能亢进症患者异位甲状旁腺的检出及分布情况分析[J]. 中华临床医师杂志(电子版), 2023, 17(04): 381-385.
[12] 张赟辉, 罗军, 刘栗丽, 汪宏, 耿克明. 腹膜透析与血液透析对老年终末期肾病患者营养状况及炎症反应的影响[J]. 中华临床医师杂志(电子版), 2023, 17(04): 419-423.
[13] 彭晨健, 张伟, 陈烁, 赵建宁, 王军. 多学科协作诊治模式在老年髋部骨折合并肾功能衰竭透析患者髋关节置换治疗中的应用[J]. 中华老年病研究电子杂志, 2023, 10(02): 19-23.
[14] 黄炎驱, 司徒对苗, 余丹红, 林延明. 高通量血液透析对老年肾代谢和少肌性肥胖的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 126-130.
[15] 刘倩影, 刘雪彦, 周佩如, 胡申玲, 叶倩呈, 黄洁微. 糖尿病肾病患者血液透析期间低血糖管理的证据总结[J]. 中华肥胖与代谢病电子杂志, 2023, 09(01): 22-27.
阅读次数
全文


摘要